Caris Life Sciences, Inc.
CAI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 19.5% | 50% | 20.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 68% | 62.7% | 47.2% | 37.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Income | $0 | $0 | -$0 | $0 |
| % Margin | 15.1% | 9.9% | -47.9% | 67% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 11.2% | -39.6% | -84.8% | -66.2% |
| EPS | 0.086 | -1.93 | -0.4 | -0.35 |
| % Growth | 104.5% | -382.5% | -14.3% | – |
| EPS Diluted | 0.082 | -1.87 | -0.4 | -0.35 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 19.7% | -25.5% | -68.4% | -40.9% |